Filing summary
Entity and period: The supplied filing is Oculus Innovative Sciences, Inc.’s Form 10-K for the fiscal year ended March 31, 2014—not a filing identified as Sonoma Pharmaceuticals, Inc. or a standalone 2013 fourth-quarter report. The filing reports annual results; it does not provide a clear standalone Q4 financial summary. Financial statements are audited, with an unqualified opinion.
Business context
Oculus developed and sold healthcare products based primarily on its Microcyn technology, including wound-care, dermatology and animal-health products, in more than 20 countries. It also operated a contract testing laboratory. Most Microcyn products had U.S. FDA 510(k) medical-device clearances, but the company did not have U.S. approval to market Microcyn as a drug or for U.S. antimicrobial or wound-healing indications.
On March 26, 2014, Ruthigen completed its IPO, reducing Oculus’s ownership to approximately 43%. Oculus deconsolidated Ruthigen and recognized a $11.133 million gain; its retained 2 million shares were recorded as a $10.150 million investment.
Financial performance
| Metric | FY ended March 31, 2014 | FY ended March 31, 2013 |
|---|---|---|
| Total revenue | $13.668 million | $15.452 million |
| Gross profit | $8.397 million; 61% of revenue | $10.743 million; 70% of revenue |
| Operating expenses | $14.448 million | $14.117 million |
| Loss from operations | $(6.051) million | $(3.374) million |
| Net income (loss) | $3.735 million | $(5.431) million |
| Operating cash flow | $(4.890) million | $1.150 million |
| Cash and cash equivalents at year-end | $5.480 million | $7.900 million |
| Working capital at year-end | $1.970 million | Not stated here |
| Total liabilities at year-end | $8.728 million | $8.484 million |
Product revenue, including licensing fees, was $12.723 million, down 13%. U.S. product revenue fell 22% to $5.340 million; Mexico declined 11% to $5.259 million; Europe and the rest of the world increased 15% to $2.124 million. Service revenue rose to $945,000 from $869,000. Management separately reported Microcyn product gross profit of $8.213 million, or 65% of product revenue, versus $10.607 million, or 73%, in the prior year; lower Mexico margins following the More Pharma transaction and weaker U.S. revenue contributed to the decline.
Reported net income chiefly reflected the non-cash $11.133 million Ruthigen deconsolidation gain. The business remained loss-making from operations, and operating cash use was $4.890 million. Research and development expense increased 30% to $2.887 million, including $1.378 million of Ruthigen-related expense; management expected R&D spending to decline after the separation. Selling, general and administrative expense decreased 3% to $11.561 million.
Debt, liquidity and financing
At March 31, 2014, reported long-term debt was $147,000, of which $143,000 was current. The Venture Lending & Leasing debt and associated future interest were settled in December 2013; remaining debt primarily related to financing insurance premiums. Cash fell by $2.420 million during the year. Financing activities provided $2.945 million, including equity-offering proceeds and warrant exercises, offset in part by $1.615 million of debt principal payments.
Management said cash was expected to fund working capital, sales and marketing, and R&D through at least April 1, 2015. It also said additional capital might be needed for longer-term development and market expansion, with no new financing commitment secured at the filing date. After year-end, Oculus entered an at-the-market offering agreement for up to $9.159 million; by June 24, 2014, it had sold 300,000 shares for net proceeds of approximately $982,000.
Material changes, outlook and risks
- Innovacyn transition: Innovacyn represented approximately 23% of FY2014 revenue, or $3.1 million. In April 2014, it notified Oculus that it intended to transition to another supplier over the following 12 months. Oculus was negotiating a transition arrangement and seeking replacement distribution; revenue could be adversely affected.
- Ruthigen separation: Oculus retained a minority investment subject to transfer restrictions, including a one-year lockup and additional restrictions thereafter. Its reported value may fluctuate, and the shares may not be readily convertible to cash. The license arrangement includes up to $8 million in contingent milestone payments and royalties of 3%–20% on qualifying product sales.
- Funding and continuing losses: The company reported a $134.010 million accumulated deficit and expected continued losses. Management stated pivotal U.S. drug trials would be delayed until a strategic partner or other funding was obtained.
- Revenue concentration: Two customers accounted for 38% and 23% of FY2014 net revenue. Three customers represented 44%, 15% and 12% of year-end net receivables.
- Regulatory and commercial exposure: U.S. drug approval would require further studies and FDA review. Market adoption, reimbursement, partner performance, manufacturing compliance, international regulation and foreign exchange were identified as risks. Prior clinical evidence included studies that were not consistently designed to FDA drug-approval standards.
- Unusual accounting items: A $1.566 million non-cash loss from remeasuring warrant derivative liabilities partly offset the Ruthigen gain. The Ruthigen investment was recorded at cost after deconsolidation, and management reported no impairment at year-end.
- Other items: A Mexico lawsuit was dismissed in 2014 for inactivity. The company disclosed a prior FDA Class II labeling recall of selected product lots, described as having nominal cost and no material revenue impact. Management concluded disclosure controls and internal control over financial reporting were effective as of March 31, 2014.
Investor verification checklist
- Confirm the issuer and reporting period: this source is Oculus Innovative Sciences’ FY2014 10-K, not a Sonoma Pharmaceuticals filing or standalone 2013 Q4 report.
- Assess how much of FY2014 net income depended on the non-cash Ruthigen deconsolidation gain, and reconcile reported earnings with operating losses and cash use.
- Track Innovacyn’s supplier transition, replacement-partner progress and the resulting revenue impact.
- Review cash burn, the stated April 1, 2015 liquidity horizon, subsequent ATM proceeds and any need for further financing or dilution.
- Examine customer and receivable concentration, including collection risk, and the restrictions and valuation basis for the Ruthigen shares.
- Monitor gross-margin trends, U.S. regulatory progress and whether clinical evidence supports the company’s commercial claims and future approvals.